LYON, France--(BUSINESS WIRE)--Flamel Technologies (Nasdaq: FLML) announced today that a payment of $500,000 has been triggered in connection with the license agreement it signed in 2007 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). The agreement is for the development of a marketed protein to be delivered using Flamel’s Medusa technology. Flamel also is receiving additional revenues from Wyeth for work being conducted on the development of the Medusa-enabled formulation of the protein.
